Session 204
Enabling Seamless Internal and External Collaboration in a Rapidly Growing Organization
External innovation is a key pillar of BeiGene's corporate strategy, and partnering has played an important role in the organization's growth to date. Although only ten years old, BeiGene has 19 strategic alliances, and over 5,000 team members across 23 offices on five continents. Over the past six months, BeiGene and Vantage Partners have been working together to blueprint an integrated strategy, business development, and alliance management function. This endeavor promotes seamless collaboration both internally and with partners and ensures BeiGene can continue to grow and explore external innovation to develop new therapies and address unmet medical needs globally.
This presentation will:
- Briefly overview BeiGene's first ten years and plans for the coming decade
- Discuss the challenges and opportunities of leading an alliance management function in a company that leverages the power of partnerships to drive growth
- Review key outputs from the Blueprint project and talk about identifying and removing static as part of creating a cross-cultural, geographically dispersed, high achieving team
Speaker:
Mike Ellis, Ph.D.
Vice President, Strategic Alliances (ISV & GSI)
BeiGene
Mai-Tal Kennedy
Principal
Vantage Partners
Mai-Tal Kennedy is a Principal at Vantage Partners, where she helps clients to collaborate more effectively–both internally and with alliance partners. Mai-Tal has worked primarily in alliance and relationship management since graduating from Law School in 2012, and has supported organizations across a variety of industries to launch and transform their alliances, as well as build Alliance Management teams and organizational capability. She is a magna cum laude graduate of Mount Holyoke College, and prior to joining Vantage Partners in early 2018 was a Senior Manager with KPMG.
Most recently, Mai-Tal has been focused on R&D alliances between academic institutions and industry, as well as alliances spanning new drug modalities. She is a values-driven consultant working to help create positive impact in her personal and professional communities, and is looking forward to connecting with many of you (albeit virtually).